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Abstract
Preoperative chemoradiation significantly improves oncological outcome in locally advanced rectal cancer. However there is
no effective method of predicting tumor response to chemoradiation in these patients. Peripheral blood mononuclear cells
have emerged recently as pathology markers of cancer and other diseases, making possible their use as therapy predictors.
Furthermore, the importance of the immune response in radiosensivity of solid organs led us to hypothesized that
microarray gene expression profiling of peripheral blood mononuclear cells could identify patients with response to
chemoradiation in rectal cancer. Thirty five 35 patients with locally advanced rectal cancer were recruited initially to perform
the study. Peripheral blood samples were obtained before neaodjuvant treatment. RNA was extracted and purified to
obtain cDNA and cRNA for hybridization of microarrays included in Human WG CodeLink bioarrays. Quantitative real time
PCR was used to validate microarray experiment data. Results were correlated with pathological response, according to
Mandards criteria and final UICC Stage (patients with tumor regression grade 1–2 and downstaging being defined as
responders and patients with grade 3–5 and no downstaging as non-responders). Twenty seven out of 35 patients were
finally included in the study. We performed a multiple t-test using Significance Analysis of Microarrays, to find those genes
differing significantly in expression, between responders (n = 11) and non-responders (n = 16) to CRT. The differently
expressed genes were: BC 035656.1, CIR, PRDM2, CAPG, FALZ, HLA-DPB2, NUPL2, and ZFP36. The measurement of FALZ
(p = 0.029) gene expression level determined by qRT-PCR, showed statistically significant differences between the two
groups. Gene expression profiling reveals novel genes in peripheral blood samples of mononuclear cells that could predict
responders and non-responders to chemoradiation in patients with locally advanced rectal cancer. Moreover, our
investigation added further evidence to the importance of mononuclear cells’ mediated response in the neoadjuvant
treatment of rectal cancer.
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Introduction
Preoperative chemoradiotherapy is the recommended standard
therapy for patients with locally advanced rectal cancer (LARC).
However, recently studies suggested that preoperative chemor-
adiotherapy (CRT), as compared with postoperative chemora-
diotherapy, improved local control and were associated with
reduced toxicity [1–6]. After neoadjuvant CRT the ability to
achieve pathologic downstaging, or a complete pathologic
response, is correlated with improved survival, decreased local
recurrence, and a higher rate of sphincter-preserving surgeries [7–
9].
Approximately 40–60% of LARC patients treated with
neoadjuvant CRT achieve some degree of pathologic response.
However, there is no effective method of predicting which patients
will respond to neoadjuvant CRT. Prospective identification of
patients who have a higher likelihood of responding to preoper-
ative CRT could be important in deceasing treatment morbidity
and improving survival and local control in LARC. In addition,
patients who are unlikely to respond could be offered alternative
approaches to therapy.
Peripheral blood mononuclear cells (BCs) comprise the circu-
lating mononuclear cells, including monocytes, T-cells, B-cells,
and natural killer cells, and have emerged in recent years as
surrogate markers of several diseases including inflammatory (e.g.
rheumatoid arthritis, and chronic pancreatitis) and malignant
diseases like renal cell carcinoma [10–12]. However, in contrast to
tissue markers, their role in prediction and prognostic assessment
of solid tumors remains limited to recent investigations using gene
chips which focus on breast, esophageal, pancreatic and colorectal
cancers [13–16].
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In the present study, we test if the gene expression profile of BCs
could identify response to CRT and, therefore, be a predictor
marker in the multidisciplinary treatment of patients with LARC.
Materials and Methods
Patients and Tumour Characteristics
The group of study initially consisted of 35 locally advanced
rectal cancer (LARC) patients from the Division of Colon & Rectal
Surgery, HUVN, Granada, Spain, with additional 8 patients of the
validation group. To qualify for this study, rectal carcinomas had
to be on the stage II or stage III according the criteria of the
International Union Against Cancer’s (UICC), without systemic
metastases in the positron emission tomography scan and no
known second neoplasm. The diagnosis of rectal cancer was
confirmed by the histopathological analysis of endoscopic biopsies.
The study was approved by the Hospital Universitario Virgen de
las Nieves - Granada ethics committee. Written informed consent
was obtained from all patients before the study. After the initial
staging, all patients qualifying for this study received neoadjuvant
radiotherapy (28 fractions of 1.8 Gy, 5 fractions/week) with
concomitant chemotherapy (capecitabine, 825 mg/m2, twice daily
alone or in combination with oxaliplatine 50 mg/m2 once weekly).
Standardised surgery, including total mesorectal excision, was
performed 8 weeks after the standardised CRT protocol described
above.
Standard pathologic tumor staging of the resected specimen was
performed according to UICC guidelines and the tumour
regression grade (TRG). Mandard classifications were assigned
by at least one specialized gastrointestinal pathologist. For this
study, patients with TRG 1 and 2 and downstaging were
considered as responders whereas patients classified with regres-
sion grades 3 to 5 and no downstaging were treated as non-
responders. Downstaging was defined as reduction of pathologic
staging (ypStage) in relation to pretreatment stage (cStage) (i.e., cII
to ypI, cIII to ypII or ypI).
Isolation of RNA from BCs
Total RNAs were extracted from 12 mL of peripheral blood
mononuclear cells (BCs) samples before treatment from each study
participant using PAXgene Blood RNA System (PreAnalytix,
Becton Dickinson, San Diego, CA, USA) according to manufac-
turer’s instructions. Quantity and integrity of RNAs were checked
by spectrophotometry in a NanoDropTM (ND-1000, DE, USA)
and in an ExperionTM automated electrophoresis system (Bio-
Rad, Richmond, VA, USA), respectively.
Gene Expression Analysis
In brief, following reverse transcription cRNAs were labeled
with Cy5 Streptavidine (Amersham Biosciences, Sweden). Hy-
bridization of whole genome human genes included in CodeLink
bioarrays (Applied Microarrays, Tempe, AZ, USA) was performed
overnight at 37uC in a shaker incubator (Innova 4080, New
BrunswickH, NJ, U.S.A.). The hybridization reactions were done
in duplicate. Microrrays were read with a GenePix 4000B laser
scanner (Axon Instruments, CA, USA), quantified and normalized
using CodeLink Software 5.0 (Applied Microarrays, Tempe, AZ,
USA). Microarray data were normalized using different methods:
average normalization and cyclicLoess. The quality of the
outcome was assessed by different plots produced by the software
package ArrayQualityMetrics implemented in the R language. A
supervised method (Significance Analysis of Microarrays -SAM-)
[17] was then used to find the more significant (adjusted p,0.05)
differentially expressed genes in rectal cancer patients who
responded to treatment and those who did not.
Upon concluding this process the raw gene expression values
were obtained for each of the samples. This dataset has been made
publicly available at the Gene Expression Omnibus GEO
database [18] with submission number GSE44172.
Correlation of Gene Signatures to CRT Response
Samples were grouped into the two categories according to
response to treatment. The differential expression of genes was
then evaluated for the proposed categories using the software SAM
(Significance Analysis of Microarrays, Stanford University, CA,
USA) [17]. The cut-off for significance was determined by tuning
the parameter delta (D), which was chosen based on the False
Discovery Rate (FDR). Genes with corrected p-values ,0.05 were
considered as significantly differentially expressed between the
groups.
Validation of Microarray Data by qRT-PCR
We used quantitative Real Time PCR (qRT-PCR) to confirm
some of the results found in the microarray gene expression
profile. We optimized a sensitive and specific qRT-PCR assay
using MX3005P QPCR System (Stratagene, Agilent Technolo-
gies, La Jolla, CA, USA). One microgram of RNA was used for
reverse transcription with QPCR-grade AffinityScriptH Multiple
Temperature Reverse Transcriptase (AffinityScriptH QPCR
cDNA synthesis kit, Stratagene, Agilent Technologies, La Jolla,
CA, USA) using random hexamers. PCR reactions contained 1 mg
cDNA, 12.5 mL Brilliant IIH qPCR Master Mix (Stratagene,
Agilent Technologies, La Jolla, CA, USA), 1.25 mL SolarisH
(Dharmacon, Thermo Scientific, Chicago, IL, USA) primer/probe
set for each gene. PCR conditions were 15 min at 95uC, 15 s at
Table 1. Specific TaqmanH primers and probes used in
quantitative RT-PCR assays of over-expressed genes in BCs
samples from responder rectal cancer patients before
treatment.
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95uC and 1 min at 60uC for 40 cycles. We designed specific
TaqmanH probes and primers (Table 1). Before performing this
study GAPDH (RT-CKYD-GAPD, Yakima YellowH Eclipse
Dark QuencherH), RPL13A (RT-CKYD-RPL13A Yakima Yel-
lowH Eclipse Dark QuencherH) and TBP (RT-CKYD-TBP
Yakima YellowH Eclipse Dark QuencherH) genes were selected
as a candidate housekeeping gene. Despite the fact that GAPDH is
over-expressed in BCs of several malignancies such as cervical and
ovarian cancers [19], GAPDH emerged as the most stable gene,
with no closely comparable housekeeping gene among the
evaluated genes in a series of tumors.
Expression was quantified following the analysis of two different
dilutions of cDNAs (1 and 1/10) in triplicate. For each
experimental sample, the amount of the each gene and
endogenous reference (GAPDH) was determined from the
standard curves. These standard curves were composed of five
points obtained from five-fold serial dilutions (1, 1/10, 1/50, 1/
100, and 1/500) of cDNA from Universal Human Reference RNA
(Stratagene, Agilent Technologies, La Jolla, CA, USA). It is
composed of total RNA from 10 human cell lines. We considered
only experiments in which the linear relationship between Ct
(threshold cycle) and the log of the amount of standard curve for
each gene and GAPDH were higher than 0.99 (correlation
coefficient). The expression values of each gene were then divided
by the amount of GAPDH to obtain a normalized value. GAPDH
gene was used as an internal control for RNA quality reverse
Table 2. Patients and tumour characteristics.
Pat N Sex Age CRT cTN Surg TRG Downst Resp Leuc Lymp
1 Male 63 capox T4N1 LAR 2 Yes 5,2 34,4
2 Male 71 cap T3N0 LAR 2 Yes Yes 8,4 17
3 Male 77 cap T3N1 LAR 4 Yes Yes 8,4 25,3
4 Male 67 cap T3N0 LAR 5 No No 6,8 25,7
5 Female 83 cap T3N0 APR 2 Yes No 5,1 32,1
6 Female 63 cap T3N2 LAR 5 No Yes 6,7 39,6
7 Male 51 capox T4N0 APR 2 Yes No 9,7 22,2
8 Male 53 capox T3N1 LAR 1 Yes Yes 7 32,1
9 Male 64 capox T3N2 HART 2 No Yes 8,5 24,5
10 Male 69 cap T3N0 HART 3 Yes Yes 8,9 27,7
11 Male 69 cap T3N0 LAR 1 Yes No 6,9 33,1
12 Male 59 cap T3N0 APR 4 Yes Yes 7,9 28,6
13 Male 71 cap T3N0 LAR 5 Yes No 7,7 32,3
14 Female 62 cap T3N1 HART 5 Yes No 12,2 12,3
15 Female 58 cap T3N0 LAR 1 Yes No 7,1 47
16 Male 50 capox T4N0 APR 4 No Yes 8,5 12,5
17 Male 36 capox T4N0 HART 5 No No 11,6 36,2
18 Male 47 capox T3N0 LAR 4 No No 9,8 21,1
19 Male 45 capox T3N0 APR 5 No No 10 20,4
20 Male 47 capox T3N1 HART 1 Yes No 9 17,3
21 Male 74 cap T3N0 HART 4 Yes Yes 6 26,6
22 Female 61 cap T3N1 LAR 4 No Yes 2,1 33,1
23 Female 37 capox T3N2 LAR 5 No No 5,2 32
24 Male 54 cap T3N0 LAR 1 Yes No 7,6 34,8
25 Male 69 capox T3N2 APR 3 No Yes 5,7 21,6
26 Female 70 cap T3N2 LAR 3 Yes No 8 25,8
27 Male 61 capox T3N1 LAR 2 Yes No 8 30,4
28 Female 76 cap T3N0 LAR 4 Yes Yes 5,24 16,6
29 Female 64 cap T3N2 LAR 4 No No 7,64 12,3
30 Male 63 cap T3N1 LAR 2 Yes No 4 18,3
31 Female 56 cap T2N1 LAR 3 Yes Yes 5,66 26,5
32 Male 62 cap T3N1 LAR 4 No No 4,19 21,7
33 Male 64 cap T3N2 LAR 3 No Yes 3,25 17,8
34 Male 56 cap T4N1 LAR 3 Yes No 6,21 15,6
35 Male 62 cap T3N1 LAR 4 No No 10,44 5,1
CRT: Chemoradiation; Cap: Capecitabine; Capox: Capecitabine and Oxaliplatine; cTN: clinical stage, Surg: surgical technique, LAR: Low anterior resection, APR: Abdmino-
perineal resection; HART: Hartmann, TRG: Tumor Regression Grade; Downst: Downstaging; Resp: response, Leuc: leucocytes (61036ml), Lymp: lymphocytes (%).
doi:10.1371/journal.pone.0074034.t002
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transcription and to correct the variations in the degree of RNA
degradation. Statistical significance of differences in transcript
levels was assessed using the non-parametric T-test (Mann
Whiteney). Data analyses were carried out with the SPSS statistical
software, version 15.0 (SPSS Inc., Chicago, IL, USA). To perform
quantification of the expression of genes, a standard curve was
constructed with at least four different concentrations in triplicate.
The GAPDH gene was used as control gene to test the quality of
cDNAs. Expression was estimated after the analysis of two
different dilutions of the cDNAs, each one of the dilutions
analyzed in triplicate. Differences in gene expression between
Responder and Non-responder groups were estimated using non-
parametric T-test.
Results
Patients and Tumor Characteristics
Eight of the 35 initial patients were finally excluded due to the
poor quality of the RNA or contradictory results of Mandards
criteria and histopathological downstaging. Statistical power of
more than 0.8 was obtained with these 27 patients.
Clinical data of the final 27 patients are shown in Table 2,
further including the 8 patients of the validation group (patient 28
to 35). Note that the postoperative UICC stage represents tumor
stage after neoadjuvant treatment (ypT). No statistically significant
differences (chi square) were found in terms of CRT, surgery or
sex when comparing between the two groups (response vs. non-
response) (Table 3). Furthermore, no significant differences (t-
student) were found in total leukocyte number and haemoglobin
between both groups (responders and non-responders) (Table 4).
Differential Gene Expression in Peripheral Blood Samples
between Treatment Responder and Non-responder
Patients with Rectal Tumour
A supervised method (Significance Analysis of Microarrays -
SAM-) was used to search for a gene signature showing significant
differences between expression profiles for responder and non-
responder patient subgroups. We found that 8 genes were
differentially expressed (p,0.05) in BCs from responder and
non-responder samples. All these genes presented significantly
higher expression levels (over-expression) in responder LARC
patients. Table 5 describes these 8 genes (BC035656.1, CIR,
PRDM2, CAPG, FALZ, HLA-DPB2, NUPL2, and ZFP36).
Genes BC035656.1, CIR and PRDM2 showed the highest
difference of gene expression values between the two groups
(Log-ratio: 1.47, 1.34 and 1.24 respectively).
Quantitative RT-PCR Validation
mRNA expression levels of six of the genes (CIR, PRDM2,
CAPG, FALZ, NUPL2, and ZFP36) over-expressed in treatment
responder patients were analyzed by qRT-PCR. HLA-DPB2 and
BC035656.1 were discarded due to complexity of the HLA-DP
region and sequence discontinued respectively.
The measurement of gene expression levels determined by
microarray analysis positively correlated with the qRT-PCR
analysis. Both microarray and qRT-PCR results confirmed similar
trends of gene expression profiles of selected genes in rectal cancer
patients. As occurred in the microarray expression analysis, we
found significant differences between the expression of FALZ gene
(p = 0.029) in treatment responder and non-responder groups.
CAPG (p = 0.268), CIR (p = 0.058), NUPL2 (p = 0.476), PRDM2
(p = 0.959), and ZFP36 (p = 0.063) showed higher expression in
responder patients, without ever reaching statistical significance
(Figure 1).
Validation of Predictive Biomarkers
To evaluate the prognostic relevance of FALZ, CIR and ZFP36
genes, we applied qRT-PCR. In order to reach a sufficient power
in the analysis, we have added the validation cohort (n = 8) to the
overall population studied (n = 27). According to the criteria used
(patients with Mandards TRG 1 and 2 were considered as
Table 3. Clinical data comparing both groups (responder and
non-responder). Data are presented as number of patients
(percentage).
Measurement Group Mean values 6 SE
Leukocytes (61000/mL) Responders 7.261.17 p = 0.902
Non-responders 7.3162.54
Haemoglobin (g/dL) Responders 14.9361.96 p = 0.240
Non-responders 13.7662.78
Age (years) Responders 61.469.9 p = 0.863
Non-responders 60.7611.3
doi:10.1371/journal.pone.0074034.t003
Table 4. Leukocytes (103/mL), haemoglobin (g/dL) and age values in responder (n = 12) and non-responder (n = 23) rectal cancer
patients before treatment.
No response 23(65.7%) Response 12 (34.3%) p
Drug 0.261
Capecitabine 17 (73.9%) 6 (50.0%)
Capecitabine+ oxaliplatine 6 (26.1%) 6 (50.0%)
Surgical technique 1
Anterior resection 19(82.6%) 10 (83.3%)
Abd-perineal resection 4 (17.4%) 2 (16.7%)
Sex 0.434
Women 8(34.8%) 2 (16.7%)
Men 15 (65.2%) 10(83.3%)
Data are presented as mean values 6 SD (standard deviation).
doi:10.1371/journal.pone.0074034.t004
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responders), only one of them was classified as a responder. For
each mRNA (array and qRT-PCR data) a receiver operating
characteristic (ROC) curve was generated. Area under curve
(AUC) value and 95% confidence interval (CI) were calculated to
determine the specificity and sensitivity of response to treatment
prediction. ROC curves of FALZ microarrays’ data reflected
moderate ability to distinguish between the responder subgroup
and Non-responder subgroup, with an AUC of 0.843. At a cut-off
point set at 20.72, FALZ yielded a sensitivity of 80.0% and a
specificity of 85.7%. ROC curves of FALZ qRT-PCR data had an
AUC of 0.681.
Discussion
Modern oncological treatment decisions increasingly depend on
so-called clinical and laboratory predictive and prognostic
markers. Whereas prognostic markers explain variability irrespec-
tive of treatment, our study intends to use predictive markers to
explain outcome variability in response to treatment.
Gene expression profile using the microarray technology has led
to a series of promising results through tissue gene expression
profiling of different malignancies, including cancer. Interestingly,
gene signatures have been used successfully as prognostic predictor
for patients with colorectal carcinomas [20]. In this regard,
Ghadimi et al. were able to predict response to therapy using gene
Table 5. Genes over-expressed in peripheral blood mononuclear cells from locally advanced rectal cancer patient responders.
Gene Name Log-ratio Description Code Link ID
BC035656.1 1.47 hypothetical protein LOC285835, mRNA (cDNA clone IMAGE:5588650).
Discontinued
BC035656.1
CIR 1.34 CBF1 interacting corepressor (CIR). transcript variant 1 NM_004882.3
PRDM2 1.24 UI-H-BW1-and-f-10-0-UIs1 NCI_CGAP BF514317.1
CAPG 1.24 capping protein (actin filament). gelsolin-like (CAPG) NM_001747.2
FALZ 1.14 fetal Alz-50-reactive clone 1 (FAC1) U05237.1
NUPL2 0.82 xm72b03x1 NCI_CGAP_Kid11 AW237453.1
ZFP36 0.79 zinc finger protein 36. C3H type NM_003407.1
HLA-DPB 0.72 NIA Human H1 Embryonic Stem Cell cDNA Library (Long) CD655061.1
doi:10.1371/journal.pone.0074034.t005
Figure 1. Box plots representing expression values of FALZ, CAPG, CIR, NUPL2, PRDM2, and ZFP36 genes by quantitative real-time
RT-PCR in both groups of rectal cancer patients defined by their response to treatment: responder (R), and non-responder (NR).
FALZ, CAPG, CIR, NUPL2, PRDM2, and ZFP36 expression levels were successfully obtained from 30, 13, 29, 27, 30, and 23 LARC patients. Boxes
represent the quartiles, median is represented by a black line within the box, and circles (0) show atypical values (1.5–3 times the length of the box).
Asterisk (*) shows extreme values (more than three times the box). FALZ gene expression showed statistically significant differences between
responder and non-responder patients.
doi:10.1371/journal.pone.0074034.g001
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expression profiles. Tumor behavior was correctly predicted in
83% of patients. Sensitivity (correct prediction of response) was
78%, and specificity (correct prediction of nonresponse) was 86%
[21].
Similarly, it has been repeatedly demonstrated in recent years
that genetic expression in BCs is altered in the context of
malignancy. This observation of an altered BCs genetic expression
profile in cancer patients was first reported in hematological
malignancies. Today, current publications suggest that BCs could
be valuable surrogate markers with diagnostic potential and
prognostic applications in different cancer localizations such as
renal, breast, esophageal, pancreatic and colorectal [12–16].
Nevertheless, to our knowledge, no publication has ever attempted
to investigate the genetic profile of BCs as surrogate predictive
markers of response to treatment in solid organs.
But which could be the rationale of our investigation? In this
context, it has been proposed that tumor shrinkage is not simply
dependent on direct damage to irradiated tumoral cells but that it
is also greatly affected by the host immune response [22]. In fact,
in vivo studies have suggested that cancer cells, dead or dying due
to CRT, can present tumor-associated antigens to host immune
cells and thereby evoke anti-tumor immune responses [23,24].
Moreover, mounting clinical data suggest the presence of
radiation-induced anti-tumor immunity in humans [25,26].
Since lymphocytes, especially T cells, play a central role in anti-
tumor immunity, Molling et al demonstrated that high levels of
circulating invariant natural killer T (iNKT) cells predict the
clinical outcomes of patients with head and neck squamous cell
carcinoma [27]. Moreover, specifically for rectal cancer, Kitayama
et al. [28] speculated, after observing that the percentage of
lymphocytes showed a strong association with response to CRT,
that the lymphocyte-mediated immune response against damaged
tumor cells is critically important for achieving response.
Other investigations in rectal cancer patients, studying the
increased apoptosis of lymphocytes in good responders to in vitro
irradiation, suggest that the radiosensivity of malignant cells might
be correlated with that of normal cells in rectal cancer and raise
the possibility that the cancer response to CRT may be predicted
by analyzing peripheral BCs [29].
The results reported here show that only a few genes among
several thousand tested were differentially expressed with a
statistically significant frequency between peripheral mononuclear
cells of BCs from responder and non-responder LARC patients to
CRT. Expression levels of CIR, PRDM2, CAPG, FALZ, NUPL2,
and ZFP36 were higher in responder patients. The results from
qRT-PCR showed trends that coincided with the microarray,
although the only statistically significant changes in expression
were for the FALZ gene (CIR and ZFP36 showing values close to
significance level). The relationship between the FALZ expression
and the effects of neoadjuvant treatment on rectal cancer has not
been investigated. There are, however, evidences which suggest
that they could be new molecular markers for predicting response
to neoadjuvancy in rectal cancer patients. The FALZ locus codes
various transcription factors, whose overexpression lead to
apoptosis [30], and it is known that in many tumours, apoptosis
is the main mechanism for the death of cancer cells in response to
common treatment regimens. ZFP36 induce vascular endothelial
factor (VEGF) mRNA degradation [31] and decreasing Ras-
dependent VEGF expression [32]. The VEGF reduction has been
related to prediction of efficacy of treatment with cetuximab plus
weekly irinotecan in heavily pretreated advanced colorectal cancer
patients, as well as overall survival [33]. However, further studies
are needed to conclude whether FALZ, CIR and ZFP36 are
involved in the response to therapy.
To investigate whether the gene expression profile in BCs is a
representation of the genes expressed in the tissues themselves, we
also looked for any similarity between the differentially expressed
genes identified in our study and those observed by microarray
analysis in tumor tissue of LARC patients (data not shown). We
did not find any of the eight genes that were differentially
expressed in BCs from responding and non-responding patients in
gene expression patterns of LARC tissues (unpublished data). Thus
it appears that, in general, gene expression in BCs does not mimic
that in the primary tumor and, therefore, is not an artefact of
circulating tumor cells.
On the other hand, while the addition of oxaliplatine to some
patients could reflect a drawback of the study, it should be
emphasized that the main treatment effect of RCT relies on
radiotherapy. In fact, results from phase III studies [34] outline the
importance of delivering 50.4 Gy independently of the chemo-
therapeutical agent employed (capecitabine alone or in combina-
tion with oxaliplatine).
Conclusions
In the present study we analyses gene expression profiles
obtained through whole genome-based microarrays in peripheral
BCs samples from LARC patients to evaluate their utility as
predictor of response to CRT. Our data show significant
differences in gene expression profiling when comparing respond-
ers and non-responders. Using expression microarrays we have
identified eight genes whose expression differed significantly
between responders and non-responders. One of them, FALZ
gene was corrobated using the qPCR, an independent assay and
more accurate. Interestingly, FALZ has a relevant function in anti-
tumour immunity.
As far as we know, the present study represents the first analysis
of BCs gene profile from patients with LARC depending on
response to CRT. Establishment of such differential expression has
the potential to yield a rich compendium of potential genes for
further pursuit as novel predictive markers. Moreover, the genes
identified in our study could offer new insights into the immune
system’s dysregulation in LARC.
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